Free Trial

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific logo
$44.33 -0.01 (-0.03%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$44.08 -0.25 (-0.56%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
8
Buy
21

Based on 31 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 31 analysts, 2 have given a sell rating, 8 have given a hold rating, 20 have given a buy rating, and 1 has given a strong buy rating for BSX.

Consensus Price Target

$61.43
38.59% Upside
According to the 31 analysts' twelve-month price targets for Boston Scientific, the average price target is $61.43. The highest price target for BSX is $118.00, while the lowest price target for BSX is $44.00. The average price target represents a forecasted upside of 38.59% from the current price of $44.33.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSX Analyst Ratings Over Time

TypeCurrent Forecast
11/16/25 to 11/16/26
1 Month Ago
10/17/25 to 10/17/26
3 Months Ago
8/18/25 to 8/18/26
1 Year Ago
11/16/24 to 11/16/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
20 Buy rating(s)
25 Buy rating(s)
27 Buy rating(s)
22 Buy rating(s)
Hold
8 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$61.43$70.13$75.80$124.00
Forecasted Upside38.59% Upside58.16% Upside50.08% Upside20.70% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Boston Scientific Stock vs. The Competition

TypeBoston ScientificHealthcare CompaniesBroader Market
Consensus Rating Score
2.65
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside38.59% Upside115.11% Upside14.68% Upside
News Sentiment Rating
Positive News

See Recent BSX News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/30/2026
Barclays PLC logo
Barclays
3 of 5 stars
Lower TargetEqual Weight$48.00 ➝ $45.00+4.54%
10/30/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Joshua Jennings
3 of 5 stars
DowngradeBuy ➝ Hold$56.00 ➝ $46.00+7.76%
10/29/2026
Kendall Au
Kendall Au
Not Rated
Lower TargetOutperform$70.00 ➝ $52.00+22.95%
10/29/2026Set TargetBuy$60.00 ➝ $48.00+13.50%
10/29/2026Lower TargetNeutral$48.00 ➝ $44.00+4.53%
10/29/2026Lower TargetOutperform$55.00 ➝ $50.00+18.79%
10/29/2026Set Target$55.00 ➝ $50.00+18.79%
10/29/2026Lower TargetBuy$66.00 ➝ $48.00+14.04%
10/29/2026Lower TargetOutperform$54.00 ➝ $49.00+14.79%
10/29/2026Lower TargetBuy$67.00 ➝ $57.00+35.70%
10/29/2026Lower TargetEqual Weight$48.00 ➝ $45.00+6.51%
10/29/2026Lower TargetBuy$56.00 ➝ $49.00+16.41%
10/29/2026Boost TargetOutperform$50.00 ➝ $51.00+21.16%
10/29/2026DowngradeOutperform ➝ Market Perform
10/28/2026DowngradeBuy ➝ Hold$60.00 ➝ $46.00+9.28%
10/28/2026 DowngradeOverweight ➝ Neutral$46.00+9.28%
10/28/2026Lower TargetBuy$57.00 ➝ $48.00+10.94%
10/26/2026Lower TargetBuy$60.00 ➝ $55.00+20.26%
10/14/2026Lower TargetBuy$57.00 ➝ $51.00+19.64%
10/7/2026 Lower TargetOutperform$65.00 ➝ $52.00+20.89%
10/2/2026 Reiterated RatingSell (D+)
7/31/2026DowngradeBuy ➝ Hold
7/30/2026Reiterated RatingOutperform$78.00 ➝ $57.00+23.74%
7/30/2026 Lower TargetBuy$106.00 ➝ $78.00+81.34%
7/29/2026 Lower TargetOverweight$65.00 ➝ $60.00+39.48%
7/14/2026Lower TargetBuy$71.00 ➝ $57.00+32.50%
6/12/2026Lower Target$68.00 ➝ $61.00+41.80%
6/5/2026 DowngradeHold ➝ Strong Sell
5/29/2026DowngradeOutperform ➝ Peer Perform
4/29/2026 DowngradeStrong-Buy ➝ Hold$83.00 ➝ $60.00+4.85%
2/5/2026Lower TargetOverweight$130.00 ➝ $118.00+56.29%
2/2/2026 Set Target$115.00+24.35%
10/3/2025 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:53 AM ET.


Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 13, 2026. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

  • The stock is currently trading at $44.33, which is significantly below the consensus price target of $61.43 set by Wall Street analysts who maintain a Moderate Buy rating, suggesting substantial potential for price appreciation as the market digests recent valuation adjustments.
  • Boston Scientific Co. demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.73 which met consensus estimates, while generating revenue of $5.14 billion that exceeded the expected $5.09 billion, indicating the company is maintaining profitability and meeting demand despite broader market headwinds.
  • Institutional investors are showing renewed interest in the stock, with new positions acquired by major firms such as BlackRock Inc. and Primecap Management Co. in the second quarter, and recent third-quarter filings showing new stakes from Nan Fung Trinity HK Ltd. and increased holdings by Jefferies Financial Group Inc., signaling confidence in the company's long-term stability.
  • The company maintains a healthy balance sheet with a current ratio of 1.36 and a debt-to-equity ratio of 0.42, providing financial flexibility to navigate economic uncertainties and continue investing in its medical device portfolio without excessive leverage.
  • Boston Scientific Co. continues to innovate in high-growth areas such as cardiovascular care and neuromodulation, with products like the WATCHMAN FLX Left Atrial Appendage Closure Device and spinal cord stimulator systems addressing critical unmet medical needs, which supports sustainable revenue growth in the healthcare equipment sector.

Boston Scientific
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

  • The stock has experienced a significant decline from its 52-week high of $104.61 to its current level, hitting a 52-week low of $39.57 in October 2026, reflecting a sharp drop in investor sentiment and valuation that may indicate deeper structural issues or market skepticism about future growth.
  • Recent analyst actions have been predominantly negative, with firms like Evercore, Barclays, and Royal Bank of Canada significantly lowering their price targets in late October 2026, citing concerns about slowing demand and competitive pressures, which has contributed to the stock's downward trajectory and reduced near-term upside potential.
  • Boston Scientific Co. faces legal and regulatory risks, as evidenced by the Pomerantz Law Firm investigating claims on behalf of investors in November 2026 and recent FDA Class II recalls, which could lead to increased costs, reputational damage, and potential liabilities that may impact future earnings and stock performance.
  • The company's guidance for the current fiscal year has been lowered, with preannounced earnings per share of $3.280 to $3.320 falling below the consensus estimate of $3.360, and revenue guidance of $21.2 billion to $21.4 billion below the consensus of $21.6 billion, indicating management's reduced confidence in achieving prior growth targets amid market slowdowns.
  • Short interest in the stock has increased significantly, with shares shorted rising to 35.1 million as of October 2026, representing a 2.43% short percentage of float, which suggests that a substantial portion of the market is betting against the stock's future performance and could lead to further price volatility.

BSX Forecast - Frequently Asked Questions

According to the research reports of 31 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $61.43, with a high forecast of $118.00 and a low forecast of $44.00.

31 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last twelve months. There are currently 2 sell ratings, 8 hold ratings, 20 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BSX shares.

According to analysts, Boston Scientific's stock has a predicted upside of 38.59% based on their 12-month stock forecasts.

Over the previous 90 days, Boston Scientific's stock had 5 downgrades and 1 upgrade by analysts.

Analysts like Boston Scientific more than other "healthcare" companies. The consensus rating for Boston Scientific is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BSX compares to other companies.


MarketBeat monitors more than a dozen sources for Boston Scientific analyst ratings, with the most recent rating issued on 10/30/2026.
From Our Partners